Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 03 Mar 2023 for Opiant Pharmaceuticals, INC., €132k.
Filing timeline
BuySaleMark Jason Heath Ellison
Insider track record
Disclosed buys
0
Disclosed sells
3
Signal history
Mark Jason Heath Ellison: trading record in brief
Mark Jason Heath Ellison (senior executive) discloses dealings in Opiant Pharmaceuticals, Inc. to SEC (Form 4). In total, 15 filings cover trades dated from 29 July 2019 to 2 March 2023.
No open-market purchase appears, only 3 sales worth €55k. Other entries cover 7 share grants and 1 option exercise. Since January 2023: no purchases and 3 sales on the market.
The latest filing, published on 3 March 2023, reports a transaction of €37k in Opiant Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Mark Jason Heath Ellison
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
7,015 shares@ US$20.0070.7% of flowCommon StockSEC:0001385508-23-000067:0
610 shares@ US$20.266.1% of flowCommon StockSEC:0001385508-23-000033:0
469 shares@ US$20.204.8% of flowCommon StockSEC:0001385508-23-000022:0
1,806 shares@ US$20.2018.5% of flowCommon StockSEC:0001385508-23-000013:0
2,000 shares0Common StockSEC:0001385508-22-000104:0
12,000 shares0Common StockSEC:0001385508-22-000011:0
6 of 6 declarations
